Dosing Children With Obesity or Extreme Body Size

Why Body-Size Choice Matters

A weight-based dose is not automatically appropriate for every child whose weight is unusual for their age or height. In a child with obesity, multiplying total body weight by a dose in milligrams per kilogram can produce a much larger dose than using ideal or adjusted body weight. But choosing a smaller weight measure does not make the result correct: the dose basis needs support for the drug, population, and intended exposure.

The central pharmacometric question is how body size relates to the drug’s relevant pharmacokinetic parameters. A size measure used to calculate a dose is a dosing scalar. A size covariate used in a clearance or volume model is a model covariate. They may be the same measure, but they are not interchangeable by default. A dose scalar should be justified by the dose recommendation or by a model that connects the dose to the intended exposure.

What Each Weight Measure Can—and Cannot—Represent

TBW is straightforward to measure and is the appropriate scalar when the evidence or dosing instructions establish a dose in milligrams per kilogram of TBW. It can be a poor automatic proxy for drug disposition in obesity, however, because an increase in body weight does not imply that every tissue or pharmacokinetic process increases in direct proportion. The relationship may differ among drugs and among clearance, distribution, and other determinants of exposure.

IBW provides a reference based on a child’s height and growth reference rather than on the full measured weight. For pediatric use, the calculation must specify the growth reference and the age and sex used to obtain the BMI percentile. Using an adult formula or an unspecified “ideal” weight can produce a different value. IBW is a calculation convention, not evidence that a particular drug’s clearance or distribution is proportional to IBW.

AdjBW lies between IBW and TBW when \(0<c<1\). The familiar expression \(IBW+0.4(TBW-IBW)\) is one possible convention, not a general pediatric dosing rule. Applying a familiar adult adjustment factor to a child without drug-specific or protocol support merely creates a precise-looking number. The adjustment factor should be used only when the relevant dosing method explicitly defines it or adequate evidence supports it.

For any of these measures, the calculation has to be paired with the rest of the pediatric model. Age-related maturation, organ function, and other relevant covariates may affect clearance independently of size. The earlier material on pediatric clearance scaling establishes why a size term should not be interpreted in isolation: a child’s body size alone does not summarize developmental physiology.

Connect the Scalar to the Exposure Model

A simple justification for matching a dose scalar to a model comes from linear pharmacokinetics at steady state. Assume constant bioavailability \(F\), a stable clearance \(CL\), and a regimen for which the average steady-state concentration is described by the average input rate divided by clearance. If dose rate means dose per unit time, then:

Thus, when the target average concentration and \(F\) are fixed, the required dose rate follows the model for \(CL\), not automatically the model for TBW. Suppose, for illustration, that a supported model has \(CL\) proportional to \(W^\theta\), where \(W\) is the model’s specified weight measure. Then the dose rate is proportional to \(W^\theta\). If that dose rate is divided by \(W\) to express a dose per kilogram of the same measure, the result is proportional to \(W^{\theta-1}\). A fixed milligram-per-kilogram dose is therefore consistent with this simplified relationship only when \(\theta=1\), subject to the model’s other assumptions and covariates.

This argument does not select TBW, IBW, or AdjBW. It shows why a dose basis should follow the supported relationship between size, clearance, and exposure. The assumptions matter: the relationship is for the stated linear model and target; changes in bioavailability, nonlinearity, or other covariates would need to be addressed rather than ignored.

When Is a Dose Calculation Defensible?

Before calculating a dose for a child with obesity or extreme body size, identify the source and scope of the dosing rule. A product recommendation, a validated pediatric regimen, or a model-based recommendation may specify a weight measure, an age range, a maximum dose, or an applicable body-size range. Follow those specifications as written, and check that the child and intended use fall within their scope. If the source does not state which weight to use, the omission is not a license to choose whichever scalar produces a preferred result.

When an evidence-supported pediatric model is available, inspect the definition and range of each covariate, not just the final equation. Check whether children with obesity or extreme body size were represented, whether the model’s size relationship was evaluated in that subgroup, and whether other important covariates remain applicable. A model can fit its development data well yet be unreliable for a patient far outside the covariate range. The observed range is a practical support boundary, not a guarantee that every prediction inside it is precise.

When direct evidence is limited, a dose may be calculable without being supportable. Make that distinction explicit. The appropriate next step may be to seek drug-specific guidance or additional evidence rather than to present TBW, IBW, and AdjBW calculations as equally valid recommendations. The later tutorial on dose amount and interval addresses regimen selection; here the key decision is whether the body-size basis has a defensible foundation.

Diagnostics, Alternatives, and Limits

Several checks help reveal when a proposed body-size calculation is going wrong:

• Check definitions and units. Confirm the measured weight, height units, growth reference, age, sex, and any adjustment factor. A height entered in centimeters rather than meters makes the BMI-based IBW calculation invalid unless converted.
• Check the evidence range. Compare the child’s age and body-size covariates with the range represented in the dosing evidence or model. A precise equation does not remove extrapolation.
• Check what the model actually scales. If a clearance model specifies TBW, replacing it with IBW is a new model assumption. If a regimen specifies IBW, computing the dose from TBW is a departure from that regimen.
• Check the resulting dose against protocol constraints. Apply any stated dose cap and confirm that the units and the basis for the cap are correct. A cap does not validate an otherwise unsupported weight scalar.
• Look for a systematic mismatch. If dose recommendations vary sharply depending on TBW versus IBW, that sensitivity signals an important assumption to resolve, not a reason to average the answers.

The main alternatives are not simply “use total,” “use ideal,” or “use adjusted” weight. One option is to apply a drug-specific pediatric regimen that specifies its scalar and limits. Another is to use a population model with a supported size relationship and appropriate covariates. A third is to recognize that available evidence does not justify a body-size extrapolation. These approaches answer different evidence situations; the most convenient weight formula is not inherently the best method.

Common limitations remain even when the arithmetic is correct. BMI-derived IBW is a reference calculation and does not directly measure body composition. AdjBW depends on a chosen factor that may lack pediatric validation. TBW may not reflect how a particular drug’s clearance or distribution changes with obesity. Finally, an estimate supported for one drug, age group, or range should not be carried over automatically to another.